On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
BUSINESS
Japan’s First Biosimilars for Nesp, Forteo Hit Shelves
Japan’s first biosimilar versions of the renal anemia drug Nesp (darbepoetin alfa) and the osteoporosis treatment Forteo (teriparatide) hit the market on November 27 upon their NHI price listing the same day. Kyowa Kirin’s Nesp originator and its biosame version…
To read the full story
Related Article
- Full Showdown Starts as Mylan’s Nesp Biosimilar Reaches Market
December 3, 2019
- Japan’s 1st Forteo Biosimilar Nears Market, Mochida Looks at Billion-Yen Sales
September 19, 2019
BUSINESS
- 80%-Plus Doctors Seek In-Person Meetings with Reps: Lilly Survey
April 16, 2024
- Meiji Reaffirms 2028 Launch Plan for New Vaccine Site as METI Grants Finalized
April 16, 2024
- Nxera Grants Pivlaz’s Korean Commercial Rights to Handok
April 16, 2024
- Vabysmo Set for 2025 Filing for Angioid Streaks after Japan Trial Success
April 16, 2024
- Xofluza Approved for Pediatric Use in Taiwan: Shionogi
April 16, 2024
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…